DB06679ExperimentalProtein Based Therapies
Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase. [MeSH].
- Mechanism
- Curator reviewed
Pharmacologically active on Plasminogen
- Primary indication
- Investigated for use/treatment in myocardial infarction and thrombosis.Curator reviewed
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Amediplase, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account